The analysis of nitrosamines can be challenging. Ultra-low levels of these impurities must be quantified in diverse and complex matrices. The developed methods then need to be validated to conform to GMP requirements:
- We are equipped with all the required equipment to meet these limits, including, LC MSMS and GC MSMS systems.
- We have experience with nitrosamine testing, including validating methods for sartans and ranitidine, as well as screening testing methods.
- We can provide both toxicological and analytical support for risk evaluation.
- We are a network of BioPharma Product Testing laboratories with vast capacity at multiple sites globally performs this testing under GMP requirements.
Our laboratories specialise in method development and validation for highly sensitive and specific method to
assess carcinogenic or genotoxic impurities in drug products. We regularly face the challenges of low detection levels, difficult matrices and identification of unknown impurities during the pharmaceutical method development process.
In addition to experienced pharmaceutical impurity analysis, we can support MAH with toxicological risk
assessments. Our experienced toxicologists conduct risk assessments to address extractables & leachables,
elemental impurities (ICH Q3D).